{"id":"chlorproguanil","rwe":[{"pmid":"28288632","year":"2017","title":"Unexpected selections of Plasmodium falciparum polymorphisms in previously treatment-naïve areas after monthly presumptive administration of three different anti-malarial drugs in Liberia 1976-78.","finding":"","journal":"Malaria journal","studyType":"Clinical Study"},{"pmid":"28070879","year":"2017","title":"A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.","finding":"","journal":"European journal of drug metabolism and pharmacokinetics","studyType":"Clinical Study"},{"pmid":"26599634","year":"2015","title":"Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"24787710","year":"2014","title":"Paediatric pharmacovigilance: use of pharmacovigilance data mining algorithms for signal detection in a safety dataset of a paediatric clinical study conducted in seven African countries.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"24175945","year":"2013","title":"Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review.","finding":"","journal":"Malaria journal","studyType":"Clinical Study"}],"tags":[{"label":"chlorproguanil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimalarials","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["chlorproguanil"],"offLabel":[],"synonyms":["chlorproguanil"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"chlorproguanil","explanation":"Think of it like a roadblock for the parasite's growth. Chlorproguanil blocks an enzyme that the parasite needs to make its own DNA, which is essential for it to multiply and cause illness. Without this enzyme, the parasite can't grow and multiply, allowing the body's immune system to fight it off.","oneSentence":"Chlorproguanil works by inhibiting the enzyme dihydrofolate reductase, which is necessary for the growth and replication of malaria parasites.","technicalDetail":"Chlorproguanil acts as a competitive inhibitor of dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate, which is necessary for the synthesis of purines and thymidylate, essential for DNA replication and cell division in Plasmodium species."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/620","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CHLORPROGUANIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLORPROGUANIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:35:41.088819","biosimilars":[],"competitors":[],"genericName":"chlorproguanil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00126971","phase":"PHASE1","title":"Chlorproguanil-Dapsone in Pregnant Women","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-07","conditions":["Malaria"],"enrollment":132,"completionDate":""},{"nctId":"NCT00361114","phase":"PHASE3","title":"IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.","status":"TERMINATED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2006-07","conditions":["Malaria"],"enrollment":112,"completionDate":"2007-10"},{"nctId":"NCT00158574","phase":"PHASE2,PHASE3","title":"Kilimanjaro IPTi Drug Options Trial","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2005-01","conditions":["Malaria"],"enrollment":2419,"completionDate":"2008-06"},{"nctId":"NCT00158561","phase":"PHASE3","title":"Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2004-02","conditions":["Malaria","Vivax Malaria"],"enrollment":750,"completionDate":"2006-03"},{"nctId":"NCT00146731","phase":"PHASE3","title":"A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2004-01","conditions":["Malaria"],"enrollment":310,"completionDate":"2007-09"},{"nctId":"NCT00519467","phase":"PHASE2","title":"Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":["Malaria"],"enrollment":120,"completionDate":"2005-02"},{"nctId":"NCT00371735","phase":"PHASE3","title":"Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":["Malaria, Falciparum"],"enrollment":900,"completionDate":"2007-05"},{"nctId":"NCT00344006","phase":"PHASE3","title":"Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":["Malaria, Falciparum"],"enrollment":1395,"completionDate":"2007-08"},{"nctId":"NCT00393679","phase":"PHASE3","title":"Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2007-07","conditions":["Fever","Malaria"],"enrollment":4112,"completionDate":"2009-12"},{"nctId":"NCT00111163","phase":"NA","title":"Intermittent Preventive Treatment With Antimalarials in Kenyan Infants","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":["Malaria","Anemia"],"enrollment":1516,"completionDate":"2008-03"},{"nctId":"NCT00164359","phase":"PHASE4","title":"Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-04","conditions":["Malaria, Falciparum"],"enrollment":212,"completionDate":"2005-09"},{"nctId":"NCT00164710","phase":"PHASE4","title":"Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-04","conditions":["Malaria, Falciparum"],"enrollment":365,"completionDate":"2005-09"},{"nctId":"NCT00461578","phase":"NA","title":"Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2005-04","conditions":["Malaria"],"enrollment":800,"completionDate":"2006-10"},{"nctId":"NCT00118794","phase":"PHASE3","title":"Lapdap and Coartemether for Uncomplicated Malaria","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2004-09","conditions":["Malaria"],"enrollment":1200,"completionDate":"2005-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"002944","UNII":"8O3249M729","INN_ID":"795","UMLSCUI":"C0055470","ChEMBL_ID":"CHEMBL1213553","DRUGBANK_ID":"DB12314","PUBCHEM_CID":"9571037","MESH_SUPPLEMENTAL_RECORD_UI":"C007030"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":117,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2017 Mar 13","pmid":"28288632","title":"Unexpected selections of Plasmodium falciparum polymorphisms in previously treatment-naïve areas after monthly presumptive administration of three different anti-malarial drugs in Liberia 1976-78.","journal":"Malaria journal"},{"date":"2017 Oct","pmid":"28070879","title":"A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.","journal":"European journal of drug metabolism and pharmacokinetics"},{"date":"2015","pmid":"26599634","title":"Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.","journal":"PloS one"},{"date":"2014","pmid":"24787710","title":"Paediatric pharmacovigilance: use of pharmacovigilance data mining algorithms for signal detection in a safety dataset of a paediatric clinical study conducted in seven African countries.","journal":"PloS one"},{"date":"2013 Nov 1","pmid":"24175945","title":"Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review.","journal":"Malaria journal"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CHLORPROGUANIL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chlorproguanil is a small molecule drug in the chlorproguanil class, originally developed by an unknown entity. Its current owner is also unknown. The exact target of chlorproguanil is not specified, but it is used to treat malaria. The commercial status of chlorproguanil is unclear, with unknown patent status and generic manufacturers. Key safety considerations are not well-documented.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}